CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. (Q53248259)

12 May 2018

title

CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. (English)

1 reference

12 May 2018

author

Anja Bosserhoff

4

1 reference

12 May 2018

author name string

Rajeswara Rao Pannem

1

1 reference

12 May 2018

Christoph Dorn

2

1 reference

12 May 2018

Kristofer Ahlqvist

3

1 reference

12 May 2018

Claus Hellerbrand

5

1 reference

12 May 2018

Ramin Massoumi

6

1 reference

12 May 2018

language of work or name

English

0 references

publication date

8 October 2013

1 reference

12 May 2018

published in

Carcinogenesis

1 reference

12 May 2018

volume

35

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

461-468

1 reference

12 May 2018

Diagnosis and Treatment of Hepatocellular Carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Hepatocellular carcinoma pathogenesis: from genes to environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Mechanisms underlying ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Themes and variations on ubiquitylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

A genomic and functional inventory of deubiquitinating enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Deubiquitinases in the regulation of NF-κB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Over-expressing CYLD augments antitumor activity of TRAIL by inhibiting the NF-κB survival signaling in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

CYLD: a deubiquitination enzyme with multiple roles in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Ubiquitin chain cleavage: CYLD at work

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Deubiquitylation and regulation of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Tumor suppressor CYLD: negative regulation of NF-kappaB signaling and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Reduced expression of CYLD in human colon and hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

CYLD and HCC: when being too sensitive to your dirty neighbors results in self-destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Adenoviral vector expressing CYLD augments antitumor activity of TRAIL by suppression of NF-kappaB survival signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Specific expression and regulation of the new melanoma inhibitory activity-related gene MIA2 in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

The novel gene MIA2 acts as a tumour suppressor in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Sinusoidal tumor angiogenesis is a key component in hepatocellular carcinoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Mitogen-activated protein kinases in hepatocellular carcinoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Signal integration by JNK and p38 MAPK pathways in cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

JNK signaling in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

The c-jun kinase/stress-activated pathway: regulation, function and role in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

AP-1--The Jun proteins: Oncogenes or tumor suppressors in disguise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Functional analysis of the human cyclin D2 and cyclin D3 promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

ASK1-signaling promotes c-Myc protein stability during apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGT335

21 January 2018

Identifiers

DOI

10.1093/CARCIN/BGT335

1 reference

12 May 2018

1 reference

12 May 2018